These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7728268)

  • 1. Platelet transfusion refractoriness--prevention and therapeutical approaches.
    Novotny VM
    Transfus Clin Biol; 1995; 2(1):47-9. PubMed ID: 7728268
    [No Abstract]   [Full Text] [Related]  

  • 2. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
    Basire A; Picard C
    Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of the Platelet Refractory Patient.
    Forest SK; Hod EA
    Hematol Oncol Clin North Am; 2016 Jun; 30(3):665-77. PubMed ID: 27113003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet transfusion refractoriness due to graft-derived anti-HPA-2b production after allogeneic bone-marrow transplantation.
    Taaning E; Jacobsen N
    Transplant Proc; 1994 Jun; 26(3):1826. PubMed ID: 8030157
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
    Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
    Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for managing refractoriness to platelet transfusions.
    Dan ME; Schiffer CA
    Curr Hematol Rep; 2003 Mar; 2(2):158-64. PubMed ID: 12901147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ineffectiveness of platelet transfusions in the course of thrombocytopenia of central origin. Work Group coordinated by ANDEM].
    Norol F
    Transfus Clin Biol; 1995; 2(1):37-45. PubMed ID: 7728267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of platelet-reactive antibodies in patients who are refractory to platelet transfusions, and the selection of compatible donors.
    Vox Sang; 2003 Jan; 84(1):73-88. PubMed ID: 12542737
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
    Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
    Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two cases of platelet transfusion refractoriness and one case of possible FNAIT caused by antibodies against CD36 in China.
    Xia W; Ye X; Xu X; Ding H; Liu J; Deng J; Chen Y; Shao Y; Wang J; Li H; Fu Y; Santoso S
    Transfus Med; 2014 Aug; 24(4):254-6. PubMed ID: 25124074
    [No Abstract]   [Full Text] [Related]  

  • 11. The mean fluorescence intensities of anti-HLA antibodies detected using micro-bead flow cytometry predict the risk of platelet transfusion refractoriness.
    Beligaswatte A; Tsiopelas E; Humphreys I; Bennett G; Robinson K; Davis K; Bardy P
    Br J Haematol; 2013 Aug; 162(3):409-12. PubMed ID: 23651440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Earlier detection of HLA alloimmunization in platelet transfusion refractoriness by flow cytometric analysis.
    Sato S; Sakurai T; Yamamoto Y; Maekawa I; Ikeda H
    Transfusion; 2005 Aug; 45(8):1399-401. PubMed ID: 16078932
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of HLA- and HPA--matched platelets in alloimmunized patients.
    Kekomäki R
    Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractoriness.
    Mishima Y; Tsuno NH; Matsuhashi M; Yoshizato T; Sato T; Ikeda T; Watanabe-Okochi N; Nagura Y; Sone S; Kurokawa M; Okazaki H
    Transfus Apher Sci; 2015 Feb; 52(1):112-21. PubMed ID: 25467707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Causes of refractoriness to platelet transfusion.
    Friedberg RC; Mintz PD
    Curr Opin Hematol; 1995 Nov; 2(6):493-8. PubMed ID: 9372041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABSOLUTE PLATELET REFRACTORINESS ASSOCIATED WITH HLA ANTIBODIES: A CASE REPORT.
    Vora M; Ong M; Al-Delfi F; Dela Cruz N; Veillon D; Cotelingam J
    J La State Med Soc; 2016; 168(1):8-11. PubMed ID: 26986860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia.
    Kekomäki S; Volin L; Koistinen P; Koivunen E; Koskimies S; Ruutu T; Timonen T; Kekomäki R
    Eur J Haematol; 1998 Feb; 60(2):112-8. PubMed ID: 9508352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of platelet specific antibody (anti-Sib(a)).
    Liu D; Lu P; Wang J; Bao Y
    Chin Med J (Engl); 1996 Aug; 109(8):615-7. PubMed ID: 9206062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
    Amemiya Y
    Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HLA and transfusion: new approaches with Luminex™ technology].
    Giannoli C; Nguyen TK; Dubois V
    Transfus Clin Biol; 2011 Apr; 18(2):218-23. PubMed ID: 21397543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.